<DOC>
	<DOCNO>NCT02821000</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , overall response rate ( ORR ) pembrolizumab ( MK-3475 ) Chinese participant locally advance metastatic melanoma , disease progression follow first line chemotherapy target therapy . ORR base Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST 1.1 ) . The primary hypothesis ORR per RECIST 1.1 central independent radiology review great ORR historical control ( 10 % ) .</brief_summary>
	<brief_title>Safety Efficacy Study Pembrolizumab ( MK-3475 ) Chinese Participants With Locally Advanced Metastatic Melanoma ( MK-3475-151/KEYNOTE-151 )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Is Chinese descent , born China , Chinese home address . Has histologically confirm diagnosis locally advance ( unresectable Stage III ) metastatic ( Stage IV ) melanoma amenable local therapy . Participant may diagnosis uveal ocular melanoma . Overall proportion participant mucosa melanoma 22 % . Has fail first line chemotherapy ( exclude adjuvant neoadjuvant therapy ) target therapy melanoma . Has least one measurable lesion define RECIST 1.1 image study ( compute tomography [ CT ] magnetic resonance image [ MRI ] ) . Has performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale . Has anticipate life expectancy least 3 month . Demonstrates adequate organ function . Has provide tissue antiprogrammed cell death ligand1 ( PDL1 ) expression evaluation archival tissue sample newly obtain core excisional biopsy tumor lesion previously irradiate . Has document BRAF mutation status willing provide tumor tissue BRAF genotyping . Females may enrol study : Of nonchildbearing potential define : Is ≥45 year age menses great 2 year . Is amenorrheic &lt; 2 year without hysterectomy oophorectomy follicle stimulate hormone ( FSH ) value postmenopausal range upon screen evaluation , and/or , Is status post hysterectomy , oophorectomy tubal ligation . Female male participant childbearing potential must willing use adequate method contraception course study 120 day last dose study treatment . Note : Abstinence acceptable usual lifestyle prefer contraception participant . Has receive prior therapy antiprogrammed cell death 1 ( antiPD1 ) , antiPDL1 , antiPDL2 agent . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigation device within 4 week first dose study drug . Has prior anticancer monoclonal antibody ( mAb ) within 4 week prior first dose study drug recover ( i.e. , ≤ Grade 1 baseline ) AEs due agent administer 4 week earlier . Has chemotherapy , target small molecule therapy , radiotherapy within 2 week prior first dose study drug , recover ( i.e. , ≤ Grade 1 baseline ) AEs due previously administer agent . Has know history another ( include unknown primary ) malignancy within 5 year prior first dose study drug . ( Exceptions include adequately treated Stage 1 Stage 2 basal/squamous cell carcinoma skin , superficial bladder cancer , cancer situ undergone potentially curative therapy . ) Is expect require form systemic localize antineoplastic therapy study . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Has active autoimmune disease require systemic treatment past 2 year ( i.e. , use disease modify agent , corticosteroid immunosuppressive drug ) . Is receive systemic steroid therapy form immunosuppressive therapy within 1 week prior first dose study drug . Has active infection require intravenous systemic therapy . Has receive live vaccine within 4 week prior first dose study drug . Has know hypersensitivity component study drug another mAb . Has history ( noninfectious ) pneumonitis require steroid current pneumonitis . Is know Human Immunodeficiency Virus ( HIV ) positive . Has know active Hepatitis B C. Has know psychiatric substance abuse disorder would interfere cooperation requirement study . Is pregnant breastfeeding , expect conceive father child within project duration study , start screen visit ( Visit 1 ) 120 day last dose study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>